FDA expands indications for HemCon's bandages
This article was originally published in Clinica
The US FDA has expanded the clearance of HemCon's dressings and bandages to include their use as an antibacterial barrier against MRSA. The 510(k) clearance covers the Portland, Oregon firm's HemCon Bandages, ChitoFlex dressings and KytoStat Bandages, which are made from chitosan, a substance found in shrimp shells. The approval means that they may now be used for a wide range of other Gram-positive and –negative organisms, including Enterococcus faecalis and Acinetobacter baumanii, as well as for controlling bleeding in patients following haemodialysis. The bandages were first approved in the US in 2005 as an antibacterial barrier against Staphylococcus aureus and Klebsiella pneumonia, and are also CE marked in Europe for the original indications, along with emergency and haemodialysis use.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.